Research ArticleResearchPatient EducationWorkflow

Adding thermal ablation to TACE extended progression-free survival in unresectable liver cancer

JAMA Oncology (PubMed)Jul 30, 2026

AI-summarized from the linked source. Educational brief, not medical advice.

Brief summary

In a phase 3 randomized trial of 241 patients with liver-confined unresectable hepatocellular carcinoma, sequential thermal ablation after TACE extended median progression-free survival to 17.7 months versus 7.3 months with TACE alone.

What NurseJet pulled from the source

The open-label TORCH trial was conducted at two tertiary centers in China. TACE plus selective radiofrequency ablation also extended median overall survival to 88.6 months versus 35.1 months. Grade 3 or 4 treatment-related adverse events occurred in 23.2% and 18.3% of patients, respectively.

Why this matters for nurses

Oncology nurses coordinate preparation, symptom assessment, post-procedure surveillance, and follow-up across repeated liver-directed treatments. The survival findings strengthen the rationale for multidisciplinary review while preserving the need for patient-specific eligibility and toxicity planning.

Bedside takeaway

Sequential thermal ablation after TACE extended progression-free and overall survival in one phase 3 liver-cancer trial.

How This Applies in Practice

Use this when: Supporting a patient with liver-confined unresectable hepatocellular carcinoma through an approved TACE-ablation pathway.

On your shift

Confirm the planned procedure sequence, pre-procedure preparation, baseline symptoms, laboratory review, and responsible services.
Complete ordered access-site, pain, temperature, hemodynamic, and hepatic assessments and escalate concerning changes.
Use teach-back for expected recovery, urgent symptoms, medications, and scheduled laboratory, imaging, and oncology follow-up.

Keep in mind: Eligibility and treatment sequencing require multidisciplinary assessment, and severe treatment-related events occurred in both groups. Follow the oncology pathway, facility policy, and provider orders.

Key takeaways

The phase 3 trial randomized 241 patients with Barcelona Clinic Liver Cancer stage B disease to sequential TACE-ablation or TACE alone.
Median progression-free survival was 17.7 months with TACE-ablation and 7.3 months with TACE alone.
Median overall survival was 88.6 months and 35.1 months, respectively.
Grade 3 or 4 treatment-related adverse events occurred in 23.2% with combination treatment and 18.3% with TACE alone.

Practice implications

For patients receiving an approved TACE-ablation sequence, confirm the treatment plan and baseline assessment, complete ordered post-procedure monitoring, and escalate bleeding, severe pain, fever, hemodynamic change, or worsening hepatic symptoms. Reinforce the scheduled imaging, laboratory, and oncology follow-up plan.

Limitations & cautions

The trial was open label and conducted at two tertiary centers in China; most participants were men. Results apply to the enrolled population with liver-confined, unresectable stage B hepatocellular carcinoma and should not be generalized to other stages, tumor burdens, or ablation approaches.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations

Exact source links

Open source

Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.

JAMA Oncology (PubMed)

JAMA Oncology (PubMed). Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma: The Phase 3 TORCH Randomized Clinical Trial.

Open original source

https://pubmed.ncbi.nlm.nih.gov/42530948/

Professional education only

This summary does not replace clinical judgment, facility policy, provider orders, or official guidelines. Verify practice changes against the original source and local protocol.

Related briefs

More updates for this clinical area

Back to Discover

Journal of clinical oncology (PubMed)Sep 16, 2026Research Article

In the MATCH comparative effectiveness trial of 587 cancer survivors, both mindfulness-based cancer recovery and Tai Chi/Qigong significantly reduced post-treatment fatigue and pain interference compared to controls, with Tai Chi also significantly improving sleep quality.

Oncology Med-SurgAI summaryReview source

Research ArticleResearchPatient EducationAI summary · original source linked below

Cancer survivors frequently experience a distressing co-occurring symptom cluster of persistent fatigue, sleep disruption, and chronic pain following primary therapy. The MATCH trial (Mindfulness and Tai Chi for Cancer Health) was a partially randomized patient-preference comparative effectiveness trial evaluating Mindfulness-Based Cancer Recovery (MBCR) and Tai Chi/Qigong (TCQ) in distressed cancer survivors across diverse cancer diagnoses and stages. Enrolled participants (N = 587; mean age 60.7 years) either chose an intervention or underwent randomization to MBCR or TCQ, followed by secondary randomization to immediate intervention or waitlist control. At post-intervention, both MBCR and TCQ produced statistically significant reductions in fatigue compared to waitlist controls, with mean improvements of 3.66 points (P = .036) and 3.42 points (P = .043), respectively. Pain interference improved by more than 1 point in both active groups (MBCR: P = .029; TCQ: P = .002). TCQ also yielded a statistically significant 1.9-point improvement on the sleep quality scale after multivariable adjustment (P = .004). Clinical outcomes did not differ between MBCR and TCQ, and participant preference status did not affect intervention efficacy.

Key takeaways

Partially randomized patient-preference trial enrolled 587 distressed cancer survivors across multiple tumor types and disease stages.
Both mindfulness (MBCR) and movement-based Tai Chi (TCQ) produced statistically significant improvements in cancer-related fatigue (P = .036 and P = .043).
Both interventions achieved meaningful reductions of greater than 1 point in chronic pain interference (P = .029 and P = .002).
Tai Chi uniquely achieved a statistically significant 1.9-point improvement in overall sleep quality scale scores (P = .004).

Why this matters on shift

Oncology and outpatient clinic nurses frequently support cancer survivors struggling with debilitating symptom clusters that persist long after chemotherapy and radiation end. Confirming that both structured mindfulness and Tai Chi offer comparable, evidence-based relief for fatigue and pain interference equips nurses to guide patients toward integrative therapies matching their physical mobility and lifestyle preferences.

Bedside takeaway

In a 587-patient trial of cancer survivors, both mindfulness (MBCR) and tai chi (TCQ) significantly reduced post-treatment fatigue (p=0.036 and p=0.043) and pain interference (p=0.029 and p=0.002), with tai chi also improving sleep quality (p=0.004).

Nursing implications

Screen cancer survivors routinely for clustered symptoms of fatigue, pain, and insomnia, and discuss evidence-backed integrative referrals such as mindfulness-based recovery or Tai Chi as non-pharmacological adjuncts to symptom management.

Limitations & cautions

Partially randomized design allowed patient preference selection; waitlist comparison group rather than active sham control; symptom endpoints relied on patient-reported validated scales.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Journal of clinical oncology (PubMed). Mindfulness and Tai Chi for Sleep, Fatigue, and Pain in Distressed People After Cancer Treatment: A Partially Randomized Patient-Preference Comparative Effectiveness Trial.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

Intensive care medicine (PubMed)Oct 1, 2026Research Article

The 18-center TRANSPORT randomized trial of 187 cancer patients with septic shock found that a liberal transfusion strategy (Hb threshold 9.0 g/dL) did not improve 12-hour lactate clearance (52% vs 50%) or 28-day survival over a restrictive strategy (Hb threshold 7.0 g/dL), but increased thrombotic events from 1% to 13%.

ICU OncologyAI summaryReview source

Research ArticleResearchMedication SafetyQuality ImprovementAI summary · original source linked below

Septic shock carries high mortality among oncology patients, in whom severe anemia frequently prompts clinician concern regarding systemic tissue hypoxia. The multicenter TRANSPORT superiority randomized trial, conducted across 18 intensive care units in France, evaluated whether an early liberal red blood cell transfusion threshold (hemoglobin target 9.0 g/dL, n=93) improved tissue perfusion compared to a restrictive threshold (hemoglobin target 7.0 g/dL, n=94) during the initial 48 hours of resuscitation in adult cancer patients with septic shock (baseline lactate > 2.0 mmol/L and Hb < 9.0 g/dL). The trial was stopped prematurely for safety concerns after enrolling 187 of a planned 260 patients. Twelve-hour lactate reduction (normalization <= 2.0 mmol/L or >= 30% decrease) showed no difference between arms (52% liberal vs 50% restrictive; odds ratio 1.07; 95% CI 0.60 to 1.90; P = 0.82). Arterial or venous thrombotic complications occurred significantly more often in the liberal group (13% vs 1%; P = 0.001), while 28-day mortality remained comparable (46% liberal vs 53% restrictive; P = 0.34).

Key takeaways

Multicenter randomized trial in 18 French ICUs evaluated transfusion thresholds during initial 48 hours of septic shock in cancer patients.
Trial halted prematurely at 187 patients due to safety imbalances between study arms.
Liberal transfusion (Hb < 9.0 g/dL) failed to improve 12-hour lactate clearance (52% vs 50%, P = 0.82) or 28-day mortality (46% vs 53%, P = 0.34).
Liberal transfusion was associated with a marked increase in arterial and venous thrombotic events (13% vs 1%, P = 0.001).

Why this matters on shift

Bedside critical care nurses frequently administer blood transfusions in septic shock and monitor for complications. These findings reinforce that higher hemoglobin targets do not accelerate shock resolution even in high-risk oncology patients, and alert nurses to the substantial thrombotic hazard of unneeded liberal transfusions.

Bedside takeaway

In cancer patients with septic shock, liberal transfusion (Hb <9 g/dL) did not improve lactate clearance or 28-day survival over restrictive transfusion (Hb <7 g/dL) but raised thrombotic complications from 1% to 13%.

Nursing implications

Adhere strictly to restrictive transfusion thresholds (hemoglobin < 7.0 g/dL) during septic shock resuscitation unless provider orders or institutional protocol dictate otherwise, and maintain heightened surveillance for deep vein thrombosis or arterial occlusion if liberal transfusions are administered.

Limitations & cautions

Premature termination resulted in underpowered final sample size (187 enrolled of 260 planned); conducted exclusively within French intensive care units; limited to adult hematologic and solid oncology patients.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Intensive care medicine (PubMed). Early red blood cell transfusion strategy in septic shock among patients with cancer: the TRANSPORT randomized controlled trial.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

Palliative & Supportive Care (PubMed)Oct 9, 2026Systematic Review

A systematic review of 14 studies found that nurse-led predictive symptom management combining routine laboratory biomarkers with clinical nursing assessment enabled proactive intervention, decreased emergency department visits, and enhanced symptom control in cancer palliative care.

Oncology GeriatricsAI summaryReview source

Systematic ReviewResearchWorkflowQuality ImprovementAI summary · original source linked below

Symptom distress in advanced cancer is traditionally addressed reactively after patients report severe breakthrough pain, delirium, or severe fatigue, frequently culminating in emergency department visits and crisis hospitalizations. This PRISMA systematic review (PROSPERO CRD420261432500) synthesized 14 clinical studies—including randomized controlled trials, cohort investigations, predictive modeling, and telehealth interventions—evaluating nurse-led predictive strategies in oncology palliative care. The synthesized evidence demonstrated that monitoring objective circulating biomarkers—notably C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), serum albumin, ferritin, and electrolyte derangements—predicted impending clinical deterioration and symptom crises. When bedside and ambulatory oncology nurses paired these biomarker trends with systematic clinical judgment, patients experienced superior symptom control, fewer acute emergency department visits, and more consistent care continuity.

Key takeaways

Systematic review synthesized 14 clinical studies evaluating nurse-led predictive symptom management protocols in oncology palliative care.
Laboratory biomarkers including CRP, neutrophil-lymphocyte ratio (NLR), albumin, ferritin, and electrolytes reliably heralded impending clinical decline.
Nurse-coordinated integration of biomarker trends with structured clinical assessment shifted care from reactive firefighting to proactive symptom stabilization.
Predictive nursing models were associated with reduced emergency department admissions and improved symptom-related quality of life.

Why this matters on shift

Oncology and palliative care nurses frequently observe subtle shifts in patient functional status before acute decompensation occurs. Validating that nurses can pair objective inflammatory and nutritional biomarkers with clinical assessment transforms oncology nursing from reactive symptom relief into proactive crisis prevention, sparing fragile patients avoidable emergency room transfers.

Bedside takeaway

A systematic review of 14 studies found nurse-led predictive symptom management integrating biomarkers (CRP, NLR, albumin) with clinical judgment reduced ED visits and prevented acute decline in oncology palliative care.

Nursing implications

Review trending laboratory indicators (such as rising CRP, worsening NLR, or falling albumin) during oncology and palliative encounters as early alert signals for impending symptom crisis or disease progression, adjusting supportive care plans and symptom titration before severe functional decline develops.

Limitations & cautions

Heterogeneity in study designs, biomarker panels, and tumor types across the 14 included studies; algorithms and predictive models require standardized electronic health record integration before universal bedside adoption.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Palliative & Supportive Care (PubMed). Nursing-led predictive symptom management in oncology palliative care: Using laboratory indicators and clinical judgment to improve patient quality of life: A systematic review.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

How This Applies in Practice

Key takeaways

Practice implications

Limitations & cautions

Exact source links

More updates for this clinical area

MATCH trial of 587 cancer survivors shows mindfulness and tai chi significantly alleviate post-treatment fatigue and pain interference

TRANSPORT multicenter trial in cancer patients with septic shock finds liberal transfusion offers no lactate or survival benefit but increases thrombosis

Systematic review shows nurse-led predictive symptom monitoring using biomarkers and clinical judgment curbs oncology palliative emergencies